Actively Recruiting
Observational Study on the Natural Course of SLC6A1 Neurodevelopmental Disorder in Children and Adolescents up to 17 Years
Led by UCB Biopharma SRL · Updated on 2026-07-31
60
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a prospective longitudinal natural history study to collect clinical data on SLC6A1 Neurodevelopmental Disorder NDD, which includes epilepsy, global developmental delay, autism spectrum disorder, or intellectual disability. The study aims to understand the natural course of this condition and evaluate certain assessments to help plan future clinical studies involving patients with this disorder. Approximately 60 patients aged up to 17 years will participate, divided into two age groups under 6 years and 6 to 17 years. This noninterventional, multinational study involves an Enrollment and Baseline visit followed by five study visits over a 2-year observational period. Patients will be observed without receiving experimental treatments, and data will be collected longitudinally to characterize disease progression. The study does not include any treatment interventions but focuses on monitoring and assessments. Participants and their caregivers will be involved in baseline and follow-up visits, including completing diaries and adhering to visit schedules. Researchers will monitor seizure frequency by type and seizure-free days, as well as evaluate test completion rates, patient retention, and EEG assessments over the two years. The study is designed to track the natural development of the disorder, with safety and disease progression measures collected throughout the observation period.
CONDITIONS
Brief Title
SLC6A1-NDD Prospective Longitudinal Natural History Study
Research Team
U
UCB Cares
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here